150 related articles for article (PubMed ID: 23727257)
1. A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).
Limaye S; Riley S; Zhao S; O'Neill A; Posner M; Adkins D; Jaffa Z; Clark J; Haddad R
Oral Oncol; 2013 Aug; 49(8):835-41. PubMed ID: 23727257
[TBL] [Abstract][Full Text] [Related]
2. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
[TBL] [Abstract][Full Text] [Related]
3. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.
Argiris A; Ghebremichael M; Gilbert J; Lee JW; Sachidanandam K; Kolesar JM; Burtness B; Forastiere AA
J Clin Oncol; 2013 Apr; 31(11):1405-14. PubMed ID: 23460714
[TBL] [Abstract][Full Text] [Related]
4. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Jimeno A; Bauman JE; Weissman C; Adkins D; Schnadig I; Beauregard P; Bowles DW; Spira A; Levy B; Seetharamu N; Hausman D; Walker L; Rudin CM; Shirai K
Oral Oncol; 2015 Apr; 51(4):383-8. PubMed ID: 25593016
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
Argiris A; Buchanan A; Brockstein B; Kolesar J; Ghebremichael M; Pins M; Hahn K; Axelrod R; Forastiere A
Cancer; 2009 Oct; 115(19):4504-13. PubMed ID: 19634157
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie.
Knoedler M; Gauler TC; Gruenwald V; Matzdorff A; Schroeder M; Dietz A; Jordan WO; Arnold D; Hennemann B; Hofele C; Weissinger F; Eberhardt W; Keilholz U
Oncology; 2013; 84(5):284-9. PubMed ID: 23445718
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
[TBL] [Abstract][Full Text] [Related]
8. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
Choueiri TK; Ross RW; Jacobus S; Vaishampayan U; Yu EY; Quinn DI; Hahn NM; Hutson TE; Sonpavde G; Morrissey SC; Buckle GC; Kim WY; Petrylak DP; Ryan CW; Eisenberger MA; Mortazavi A; Bubley GJ; Taplin ME; Rosenberg JE; Kantoff PW
J Clin Oncol; 2012 Feb; 30(5):507-12. PubMed ID: 22184381
[TBL] [Abstract][Full Text] [Related]
9. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Coleman RL; Moon J; Sood AK; Hu W; Delmore JE; Bonebrake AJ; Anderson GL; Chambers SK; Markman M
Eur J Cancer; 2014 Jun; 50(9):1638-48. PubMed ID: 24709487
[TBL] [Abstract][Full Text] [Related]
10. Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer.
Fuchs H; Pammer J; Minichsdorfer C; Posch D; Kornek G; Aretin MB; Fuereder T
Med Oncol; 2018 Feb; 35(3):32. PubMed ID: 29411154
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG).
Caponigro F; Massa E; Manzione L; Rosati G; Biglietto M; De Lucia L; Sguotti C; Sganga P; Avallone A; Comella P; Mantovani G; Comella G
Ann Oncol; 2001 Feb; 12(2):199-202. PubMed ID: 11300324
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.
Machiels JP; Van Maanen A; Vandenbulcke JM; Filleul B; Seront E; Henry S; D'Hondt L; Lonchay C; Holbrechts S; Boegner P; Brohee D; Dequanter D; Louviaux I; Sautois B; Whenham N; Berchem G; Vanderschueren B; Fontaine C; Schmitz S; Gillain A; Schoonjans J; Rottey S
Oncologist; 2016 Dec; 21(12):1416-e17. PubMed ID: 27903924
[TBL] [Abstract][Full Text] [Related]
13. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.
Harari PM; Harris J; Kies MS; Myers JN; Jordan RC; Gillison ML; Foote RL; Machtay M; Rotman M; Khuntia D; Straube W; Zhang Q; Ang K
J Clin Oncol; 2014 Aug; 32(23):2486-95. PubMed ID: 25002723
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
Specht L; Larsen SK; Hansen HS
Ann Oncol; 2000 Jul; 11(7):845-9. PubMed ID: 10997812
[TBL] [Abstract][Full Text] [Related]
15. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
Clement PM; Gauler T; Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Cohen EE; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Vermorken JB;
Ann Oncol; 2016 Aug; 27(8):1585-93. PubMed ID: 27084954
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Posch D; Fuchs H; Kornek G; Grah A; Pammer J; Aretin MB; Fuereder T
Sci Rep; 2016 Sep; 6():32946. PubMed ID: 27597175
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck.
Colevas AD; Adak S; Amrein PC; Barton JJ; Costello R; Posner MR
Ann Oncol; 2000 May; 11(5):535-9. PubMed ID: 10907945
[TBL] [Abstract][Full Text] [Related]
18. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Tinhofer I; Klinghammer K; Weichert W; Knödler M; Stenzinger A; Gauler T; Budach V; Keilholz U
Clin Cancer Res; 2011 Aug; 17(15):5197-204. PubMed ID: 21653686
[TBL] [Abstract][Full Text] [Related]
19. Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.
Demirci NS; Aksoy S; Özdemir NY; Erdem GU; Ozcelik M; Tanrikulu E; Eren T; Bozkaya Y; Sahin S; Başol F; Aslan SA; Zengin N; Güllü İ
Curr Med Res Opin; 2017 Mar; 33(3):401-407. PubMed ID: 27817239
[TBL] [Abstract][Full Text] [Related]
20. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
Heymach JV; Johnson BE; Prager D; Csada E; Roubec J; Pesek M; Spásová I; Belani CP; Bodrogi I; Gadgeel S; Kennedy SJ; Hou J; Herbst RS
J Clin Oncol; 2007 Sep; 25(27):4270-7. PubMed ID: 17878479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
